Today’s Research Reports on Trending Tickers: Progenics Pharmaceuticals and Gilead Sciences

NEW YORK, NY / ACCESSWIRE / July 30, 2018 / U.S. markets plunged on Friday, after Twitter reported disappointing second quarter earnings and gross domestic product reflected fairly strong economic growth, however was lower than expected. The Dow Jones Industrial Average fell 0.30 percent to close at 25,451.06, while the S&P 500 Index was down 0.66 percent to close at 2,818.82. The Nasdaq Composite Index dropped 1.46 percent to close at 7,737.42.

“A strong GDP number—and 4.1% is still a good number, even if it was a bit below consensus—will signal that the Fed can continue with its plan for rate increases. That will be top of mind for investors today,” said director of investment management for Huntington Private Bank, Chad Oviatt.

“We remain fairly constructive about equities. Generally speaking there’s a lot of confidence about earnings growth, and the number of firms that are meeting or beating expectations, even in light of names like Facebook,” he added.

RDI Initiates Coverage on:

Progenics Pharmaceuticals, Inc.
https://rdinvesting.com/news/?ticker=PGNX

Gilead Sciences, Inc.
https://rdinvesting.com/news/?ticker=GILD

Progenics Pharmaceuticals’ stock jumped 3.37% Friday, to close the day at $7.66. The stock recorded a trading volume of 1,835,094 shares, which was above its three months average volume of 1,110,828 shares. In the last year, Progenics Pharmaceuticals’ shares have traded in a range of 4.60 – 9.12. The share price has gained 66.52% from its 52 week low. The company’s shares are currently trading above their 200-day moving average. The stock’s 50-day moving average of $8.31 is above its 200-day moving average of $7.33. Shares of Progenics Pharmaceuticals have fallen roughly 4.73 percent in the past month and are up 28.74 percent year-to-date.

Access RDI’s Progenics Pharmaceuticals, Inc. Research Report at:
https://rdinvesting.com/news/?ticker=PGNX

On Friday, shares of Gilead Sciences recorded a trading volume of 8,102,714 shares, which was above the three months average volume of 7,563,726 shares. The stock ended the day 1.73% lower at $76.81. The share price has fallen 14.22% from its 52 week high with a 52 week trading range of 64.27 – 89.54. The company’s shares are currently trading above their 200-day moving average. The stock’s 50-day moving average of $73.86 is below its 200-day moving average of $75.14. Shares of the company are trading at a Price to Earnings ratio of 29.22. Shares of Gilead Sciences have gained roughly 8.43 percent in the past month and are up 7.22 percent year-to-date.

Access RDI’s Gilead Sciences, Inc. Research Report at:
https://rdinvesting.com/news/?ticker=GILD

Our Actionable Research on Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX) and Gilead Sciences, Inc. (NASDAQ: GILD) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker-dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com

ReleaseID: 507207